Zentalis Pharmaceuticals, Inc. (ZNTL)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 25M 50M 75M Q4 '23: 0 Q1 '24: 40.6M Q2 '24: 40.6M Q3 '24: 40.6M Q4 '24: 67.4M Q1 '25: 26.9M Q2 '25: 26.9M Q3 '25: 26.9M Q4 '25: 0 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-300M -150M 0 150M 300M 450M Q3 '21: -208.6M Q4 '21: -216.5M Q1 '22: -224.1M Q2 '22: -232.4M Q3 '22: -223.7M Q4 '22: -227.3M Q1 '23: -234.4M Q2 '23: -274.8M Q3 '23: -283.3M Q4 '23: -299.5M Q1 '24: -259.3M Q2 '24: -220.6M Q3 '24: -209.3M Q4 '24: -191.2M Q1 '25: -212.1M Q2 '25: -183M Q3 '25: -165.3M Q4 '25: -152.8M Q1 '26: -145M Q2 '26: -153.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-300M -200M -100M 0 100M 200M 300M Q3 '21: -149M Q4 '21: -158.7M Q1 '22: -167.9M Q2 '22: -181.7M Q3 '22: -231.9M Q4 '22: -236.8M Q1 '23: -240.9M Q2 '23: -285.1M Q3 '23: -286.2M Q4 '23: -292.2M Q1 '24: -218.9M Q2 '24: -194.7M Q3 '24: -179.3M Q4 '24: -165.8M Q1 '25: -224.2M Q2 '25: -162.8M Q3 '25: -149.3M Q4 '25: -137.1M Q1 '26: -124.1M Q2 '26: -139.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-240M -160M -80M 0 80M 160M 240M Q3 '21: -144.4M Q4 '21: -154.1M Q1 '22: -166.8M Q2 '22: -163.7M Q3 '22: -163.4M Q4 '22: -163.8M Q1 '23: -162.8M Q2 '23: -199.1M Q3 '23: -204.6M Q4 '23: -207.8M Q1 '24: -210.5M Q2 '24: -166.4M Q3 '24: -171.8M Q4 '24: -170.9M Q1 '25: -151.5M Q2 '25: -151.1M Q3 '25: -134M Q4 '25: -125.2M Q1 '26: -125.6M Q2 '26: -128.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-240M -160M -80M 0 80M 160M 240M Q3 '21: -149M Q4 '21: -160.2M Q1 '22: -172.9M Q2 '22: -169.3M Q3 '22: -168M Q4 '22: -166.3M Q1 '23: -164.9M Q2 '23: -201.2M Q3 '23: -205.1M Q4 '23: -208.4M Q1 '24: -211.1M Q2 '24: -166.9M Q3 '24: -172.2M Q4 '24: -171.1M Q1 '25: -151.7M Q2 '25: -151.1M Q3 '25: -134M Q4 '25: -125.2M Q1 '26: -125.6M Q2 '26: -128.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q3 '20: 38M Q4 '20: 39.9M Q1 '21: 40.4M Q2 '21: 40.7M Q3 '21: 44.6M Q4 '21: 45M Q1 '22: 45.2M Q2 '22: 51.1M Q3 '22: 56.8M Q1 '23: 59.3M Q2 '23: 60.8M Q3 '23: 70.6M Q1 '24: 71.2M Q2 '24: 71M Q3 '24: 71.1M Q1 '25: 71.7M Q2 '25: 72M Q3 '25: 72.1M Q1 '26: 70.3M Q2 '26: 71.3M Q4 '20 Q3 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q3 '21: -3.68 Q4 '21: -3.78 Q1 '22: -3.85 Q2 '22: -3.85 Q3 '22: -4.72 Q4 '22: -4.53 Q1 '23: -4.29 Q2 '23: -4.80 Q3 '23: -4.63 Q4 '23: -4.54 Q1 '24: -3.33 Q2 '24: -2.72 Q3 '24: -2.49 Q4 '24: -2.32 Q1 '25: -3.13 Q2 '25: -2.26 Q3 '25: -2.07 Q4 '25: -1.90 Q1 '26: -1.73 Q2 '26: -1.95 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.